Q32 Bio

Update in progress

QTTB (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Q32 Bio Inc. is a clinical-stage biotechnology company focused on restoring healthy immune balance in alopecia areata and other autoimmune or inflammatory diseases driven by immune dysfunction. It is developing Bempikibart (ADX-914), a fully human anti–IL-7 receptor alpha antibody that completed Phase 2a, aiming to re-regulate adaptive immunity by blocking IL-7 and TSLP signaling for atopic dermatitis and alopecia areata. It also advances ADX-096, a C3d mAb-CR1 fusion for ophthalmic indications, plus other C3d mAb fusions and nanobodies for tissue-targeted complement inhibition. Founded in 2017, based in Waltham, Massachusetts.

Company score

Sentiment: 0.35; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.21; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.00; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.20; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive